How to Switch from Wegovy to Foundayo (Orforglipron)

Wegovy (semaglutide 2.4mg) is currently the most effective single-agent GLP-1 for weight loss, with 15-17% body weight reduction in the STEP trials. So why switch?

• Supply issues — Wegovy has experienced chronic shortages since launch
• Cost — Wegovy lists at ~$1,349/month; Foundayo is ~$149-349/month (dose-dependent)
• Injection fatigue — After months or years of weekly shots, many patients want an oral option
• Maintenance strategy — Lilly positions Foundayo as ideal for weight maintenance: "Use Zepbound to lose, switch to Foundayo to maintain"
• Travel convenience — No cold chain, no sharps disposal

Trade-off to consider: Foundayo's weight loss efficacy (~12%) is lower than Wegovy's (~17%). If you're still actively losing weight, discuss timing with your doctor. Foundayo may be best suited for the maintenance phase.

Wegovy uses higher doses of semaglutide than Ozempic (2.4mg vs 2.0mg max), so the transition requires careful dose management:

Key point: Even from Wegovy 2.4mg, you'll start Foundayo at 0.8mg. The titration takes time, and there may be a 2-4 month window where your GLP-1 coverage is lower than what you had on Wegovy.

The biggest concern when switching from a high-efficacy drug like Wegovy is weight regain. Here's what the data shows and how to minimize it:

What the trials show: GLP-1 switching data suggests ~0.9kg (2 lbs) of temporary regain during transition from injectable semaglutide to oral orforglipron. This reversed once patients reached effective Foundayo doses.

Strategies to minimize regain:

• Maintain your caloric intake and exercise routine during the transition
• Titrate up Foundayo as quickly as tolerated (every 30 days minimum per label)
• Monitor your weight weekly — small fluctuations are normal, but flag >5 lb gains to your doctor
• Consider timing: if you're still in active weight loss phase, discuss whether to wait until you've plateaued

Wegovy at 2.4mg has higher side effect rates than lower-dose semaglutide. Foundayo's profile is different:

• Nausea: Wegovy 44% vs Foundayo 33.7% — significant improvement
• Diarrhea: Wegovy 30% vs Foundayo 23.1% — improvement
• Vomiting: Wegovy 24% vs Foundayo 24.0% — major improvement
• Constipation: Wegovy 24% vs Foundayo 25.4% — improvement

Overall, patients switching from Wegovy to Foundayo may see improvement in nausea and diarrhea, though constipation and vomiting rates are similar. Note these are cross-trial comparisons (ATTAIN-1 vs STEP) and have inherent limitations.